NERV Stock — Minerva Neurosciences Inc

Minerva Neurosciences Inc (NERV)

Updated October 16, 2026.

NERV is a Stock. Total return is -95.1% over the past 12.3 years, 470.1 points behind SPY at 375.0%.

Minerva Neurosciences is a clinical-stage biopharmaceutical company developing treatments for central nervous system diseases, with its lead candidate roluperidone currently in Phase 3 trials for negative symptoms in schizophrenia. As an early-stage biotech company, it does not currently distribute income to shareholders. This security typically appeals to investors seeking exposure to clinical-stage pharmaceutical development with higher risk and growth-oriented potential rather than income generation.

NERV performance versus SPY

Price and return data through 2026-10-16.

Total return is -95.1% over the past 12.3 years, 470.1 points behind SPY at 375.0%. Over the past year its total return — price change plus distributions reinvested — is -7.1%. Its deepest 1-year drawdown was 70.9%.

NERV key facts

Asset type

Stock

Asset class

Equity

Inception date

07/01/2014

Distribution frequency

None

Last close

$2.35 (as of 2026-10-16)

Market cap

$112,206,764

Average volume

85597.0

Beta

-0.118

Payout ratio

0.0%

Forward P/E

11.2108

EPS

$-36.12

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

NERV risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 70.9%.

Who may consider NERV — and who may not

It is a weaker fit for investors who need monthly cash flow (NERV does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on NERV

• All tickers starting with N

Tagged: Healthcare.

Frequently asked questions